ALPMY Quote, Financials, Valuation and Earnings

Healios KK has a net margin of -18.88% compared to Astellas Pharma's net margin of -6742.11%. Astellas Pharma's return on equity of 3.42% beat Healios KK's return on equity of -196.15%.

Astellas Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma has higher upside potential than Healios KK, analysts believe Astellas Pharma is more attractive than Healios KK.

Astellas Pharma has a beta of 0.221, which suggesting that the stock is 77.908% less volatile than S&P 500. In comparison Healios KK has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Astellas Pharma has a quarterly dividend of $0.26 per share corresponding to a yield of 5.23%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma pays 254.19% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend.

Astellas Pharma quarterly revenues are $3.4B, which are larger than Healios KK quarterly revenues of $249.2K. Astellas Pharma's net income of -$640.3M is lower than Healios KK's net income of -$16.8M. Notably, Astellas Pharma's price-to-earnings ratio is 50.19x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma is 1.36x versus 83.05x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.

PeptiDream has a net margin of -18.88% compared to Astellas Pharma's net margin of -24.41%. Astellas Pharma's return on equity of 3.42% beat PeptiDream's return on equity of 34.1%.

Astellas Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma has higher upside potential than PeptiDream, analysts believe Astellas Pharma is more attractive than PeptiDream.

Astellas Pharma has a beta of 0.221, which suggesting that the stock is 77.908% less volatile than S&P 500. In comparison PeptiDream has a beta of 0.523, suggesting its less volatile than the S&P 500 by 47.679%.

Astellas Pharma has a quarterly dividend of $0.26 per share corresponding to a yield of 5.23%. PeptiDream offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma pays 254.19% of its earnings as a dividend. PeptiDream pays out -- of its earnings as a dividend.

Astellas Pharma quarterly revenues are $3.4B, which are larger than PeptiDream quarterly revenues of $27.8M. Astellas Pharma's net income of -$640.3M is lower than PeptiDream's net income of -$6.8M. Notably, Astellas Pharma's price-to-earnings ratio is 50.19x while PeptiDream's PE ratio is 14.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma is 1.36x versus 4.93x for PeptiDream. Usually stocks with elevated PS ratios are considered overvalued.

Nxera Pharma has a net margin of -18.88% compared to Astellas Pharma's net margin of -11.44%. Astellas Pharma's return on equity of 3.42% beat Nxera Pharma's return on equity of -8.65%.

Astellas Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Astellas Pharma has higher upside potential than Nxera Pharma, analysts believe Astellas Pharma is more attractive than Nxera Pharma.

Astellas Pharma has a beta of 0.221, which suggesting that the stock is 77.908% less volatile than S&P 500. In comparison Nxera Pharma has a beta of 0.374, suggesting its less volatile than the S&P 500 by 62.646%.

Astellas Pharma has a quarterly dividend of $0.26 per share corresponding to a yield of 5.23%. Nxera Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Astellas Pharma pays 254.19% of its earnings as a dividend. Nxera Pharma pays out -- of its earnings as a dividend.

Astellas Pharma quarterly revenues are $3.4B, which are larger than Nxera Pharma quarterly revenues of $43.6M. Astellas Pharma's net income of -$640.3M is lower than Nxera Pharma's net income of -$5M. Notably, Astellas Pharma's price-to-earnings ratio is 50.19x while Nxera Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma is 1.36x versus 2.85x for Nxera Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Takeda Pharmaceutical has a net margin of -18.88% compared to Astellas Pharma's net margin of -9.79%. Astellas Pharma's return on equity of 3.42% beat Takeda Pharmaceutical's return on equity of 1.49%.

Astellas Pharma has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical has an analysts' consensus of $17.00 which suggests that it could grow by 15.46%. Given that Takeda Pharmaceutical has higher upside potential than Astellas Pharma, analysts believe Takeda Pharmaceutical is more attractive than Astellas Pharma.

Astellas Pharma has a beta of 0.221, which suggesting that the stock is 77.908% less volatile than S&P 500. In comparison Takeda Pharmaceutical has a beta of 0.223, suggesting its less volatile than the S&P 500 by 77.69%.

Astellas Pharma has a quarterly dividend of $0.26 per share corresponding to a yield of 5.23%. Takeda Pharmaceutical offers a yield of 4.52% to investors and pays a quarterly dividend of $0.34 per share. Astellas Pharma pays 254.19% of its earnings as a dividend. Takeda Pharmaceutical pays out 280.28% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Astellas Pharma quarterly revenues are $3.4B, which are smaller than Takeda Pharmaceutical quarterly revenues of $6.9B. Astellas Pharma's net income of -$640.3M is higher than Takeda Pharmaceutical's net income of -$676.5M. Notably, Astellas Pharma's price-to-earnings ratio is 50.19x while Takeda Pharmaceutical's PE ratio is 67.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Astellas Pharma is 1.36x versus 1.57x for Takeda Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.